Compare EQH & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQH | PODD |
|---|---|---|
| Founded | 1859 | 2000 |
| Country | United States | United States |
| Employees | 8000 | N/A |
| Industry | Specialty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 10.3B |
| IPO Year | N/A | 2007 |
| Metric | EQH | PODD |
|---|---|---|
| Price | $48.07 | $163.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 21 |
| Target Price | $56.82 | ★ $341.48 |
| AVG Volume (30 Days) | ★ 2.4M | 1.3M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.30 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | $43.13 | $24.55 |
| Revenue Next Year | $7.45 | $19.18 |
| P/E Ratio | ★ N/A | $121.83 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $35.20 | $138.79 |
| 52 Week High | $55.24 | $354.88 |
| Indicator | EQH | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 57.35 | 55.69 |
| Support Level | $47.09 | $141.67 |
| Resistance Level | $49.59 | $168.84 |
| Average True Range (ATR) | 1.33 | 5.46 |
| MACD | -0.09 | 0.06 |
| Stochastic Oscillator | 55.36 | 65.67 |
Equitable Holdings Inc is a financial services company providing retirement, asset management, and wealth management solutions for individual and institutional clients, operating through three segments. The Retirement segment generates the majority of revenue and offers annuities, retirement savings plans, institutional savings products, and includes the spread lending business. The Asset Management segment provides diversified investment management and related services globally through Institutional, Retail, and Private Wealth channels and reflects the business of AB. The Wealth Management segment offers advisory accounts, financial planning and advice, life insurance, and annuity products. Revenues are earned predominantly from fee income, income from investments, and insurance premiums.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.